Focus: Tempus is an AI-driven biotech company focused on drug discovery and medical devices across oncology, gastroenterology, ophthalmology, neurology, and cardiovascular indications. The company operates as a mid-stage biotech leveraging machine learning platforms to accelerate development timelines.
Profile data last refreshed 13h ago · AI intelligence enriched 1mo ago
Hot — 147 jobs added in 30d
Net +97 (147 new, 50 removed). Aggressive expansion phase.
Best suited for data scientists, AI engineers, and real-world evidence professionals seeking to build emerging precision medicine infrastructure; less ideal for those prioritizing traditional drug development or near-term clinical validation.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Tempus
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Tempus's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Tempus Reports Second Quarter 2026 Results - Business Wire
Tempus Reports Second Quarter 2026 Results Business Wire
8-K Filing: Hilton Grand Vacations Inc. (HGV) (CIK 0001674168) — EXHIBIT 10.1
EXHIBIT 10.1
Tempus AI (TEM) Leverages AI for Precision Medicine Advancements - Yahoo Finance
Tempus AI (TEM) Leverages AI for Precision Medicine Advancements Yahoo Finance
8-K Filing: Passage BIO, Inc. (PASG) (CIK 0001787297) — EXHIBIT 99.2
EXHIBIT 99.2
Is Tempus AI, Inc. (TEM) Among the Best AI Drug Discovery Stocks to Buy According to Hedge Funds? - Yahoo Finance
Is Tempus AI, Inc. (TEM) Among the Best AI Drug Discovery Stocks to Buy According to Hedge Funds? Yahoo Finance
Redditors Think Tempus AI (TEM) Still Has 10X Potential - Yahoo Finance
Redditors Think Tempus AI (TEM) Still Has 10X Potential Yahoo Finance
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Evaluation of radiomics and radiologic signatures for diagnosis and clinical outcomes in pancreatic adenocarcinoma and pancreatic neuroendocrine: A pilot study.
EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo